We are delivering innovation to patients.
The academic research that underpins PepGen’s technology was primarily focused on neuromuscular diseases. Moving forward, the company will develop novel conjugate therapeutics both independently and with partners across a board range of indications. PepGen is committed to delivering our innovative technology to patients, and to transforming disease outcomes in indications with great unmet need. Further details on our specific areas of focus will be released in due course.
PepGen’s novel peptide platform offers a delivery solution for nucleic acid therapeutics. Partnerships form an important part of our strategic approach, and we are actively seeking to work with companies who have an interest in this space.
If you would like to learn more about working with PepGen and our delivery technology, please don’t hesitate to get in touch with us.